Identifying the conditions under which antibodies protect against infection by equine infectious anemia virus

Vaccines

Volumn 2, Issue 2, 2014, Pages 397-421

  Schwartz, Elissa J ^a   Smith, Robert J ^b  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antibodies; Equine infectious anemia virus; Lentivirus; Mathematical modeling; Vaccination

Indexed keywords

CD8 ANTIGEN; NEUTRALIZING ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; EQUINE INFECTIOUS ANEMIA VIRUS; HORSE; IMMUNE SYSTEM; MUTATION RATE; NONHUMAN; RELATIVE BIOLOGIC EFFECTIVENESS; SEVERE COMBINED IMMUNODEFICIENCY; SIMULATION; VACCINATION; VIRAL CLEARANCE; VIROGENESIS; VIRUS INFECTION; VIRUS INHIBITION; VIRUS MUTATION; VIRUS NEUTRALIZATION; VIRUS REPLICATION;

EID: 85019495915     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2020397     Document Type: Article

References (47)

1. Liu, P.; Overman, R.G.; Yates, N.L.; Alam, S.M.; Vandergrift, N.; Chen, Y.; Graw, F.; Freel, S.A.; Kappes, J.C.; Ochsenbauer, C.; et al. Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J. Virol. 2011, 85, 11196-11207.
2. Tomaras, G.D.; Yates, N.L.; Liu, P.; Qin, L.; Fouda, G.G.; Chavez, L.L.; Decamp, A.C.; Parks, R.J.; Ashley, V.C.; Lucas, J.T.; et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: Virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 2008, 82, 12449-12463.
3. Leroux, C.; Cadore, J.L.; Montelaro, R.C. Equine Infectious Anemia Virus (EIAV): What has HIV's country cousin got to tell us? Vet. Res. 2004, 35, 485-512.
4. Maury, W.; Oaks, J.L. Equine infectious anemia virus pathogenesis and replication. In Lentiviruses and Macrophages: Molecular and Cellular Interactions; Desport, M., Ed.; Caister Academic Press: Norfolk, UK, 2010; pp. 251-276.
5. Mealey, R.H.; Fraser, D.G.; Oaks, J.L.; Cantor, G.H.; McGuire, T.C. Immune reconstitution prevents continuous equine infectious anemia virus replication in an Arabian foal with severe combined immunodeficiency: Lessons for control of lentiviruses. Clin. Immunol. 2001, 101, 237-247.
6. Perryman, L.E.; O'Rourke, K.I.; McGuire, T.C. Immune responses are required to terminate viremia in equine infectious anemia lentivirus infection. J. Virol. 1988, 62, 3073-3076.
7. Carpenter, S.; Chen, W.C.; Dorman, K.S. Rev variation during persistent lentivirus infection. Viruses 2011, 3, 1-11.
8. Mealey, R.H.; Leib, S.R.; Littke, M.H.; Wagner, B.; Horohov, D.W.; McGuire, T.C. Viral load and clinical disease enhancement associated with a lentivirus cytotoxic T lymphocyte vaccine regimen. Vaccine 2009, 27, 2453-2468.
9. Wu, W.; Blythe, D.C.; Loyd, H.; Mealey, R.H.; Tallmadge, R.L.; Dorman, K.S.; Carpenter, S. Decreased infectivity of a neutralization-resistant equine infectious anemia virus variant can be overcome by efficient cell-to-cell spread. J. Virol. 2011, 85, 10421-10424.
10. Taylor, S.D.; Leib, S.R.; Carpenter, S.; Mealey, R.H. Selection of a rare neutralization-resistant variant following passive transfer of convalescent immune plasma in equine infectious anemia virus-challenged SCID horses. J. Virol. 2010, 84, 6536-6548.
11. Taylor, S.D.; Leib, S.R.; Wu, W.; Nelson, R.; Carpenter, S.; Mealey, R.H. Protective effects of broadly neutralizing immunoglobulin against homologous and heterologous equine infectious anemia virus infection in horses with severe combined immunodeficiency. J. Virol. 2011, 85, 6814-6818.
12. Mascola, J.R.; Lewis, M.G.; Stiegler, G.; Harris, D.; VanCott, T.C.; Hayes, D.; Louder, M.K.; Brown, C.R.; Sapan, C.V.; Frankel, S.S.; et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 1999, 73, 4009-4018.
13. Ng, C.T.; Jaworski, J.P.; Jayaraman, P.; Sutton, W.F.; Delio, P.; Kuller, L.; Anderson, D.; Landucci, G.; Richardson, B.A.; Burton, D.R.; et al. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat. Med. 2010, 16, 1117-1119.
14. Nishimura, Y.; Igarashi, T.; Haigwood, N.L.; Sadjadpour, R.; Donau, O.K.; Buckler, C.; Plishka, R.J.; Buckler-White, A., Martin, M.A. Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: Implications for HIV-1 vaccine development. Proc. Natl. Acad. Sci. USA 2003, 100, 15131-15136.
15. Ruprecht, R.M.; Ferrantelli, F.; Kitabwalla, M.; Xu, W.; McClure, H.M. Antibody protection: Passive immunization of neonates against oral AIDS virus challenge. Methods Mol. Biol. 2009, 525, 559-566.
16. Shibata, R.; Igarashi, T.; Haigwood, N.; Buckler-White, A.; Ogert, R.; Ross, W.; Willey, R.; Cho, M.W.; Martin, M.A. Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys. Nat. Med. 1999, 5, 204-210.
17. Schwartz, E.J.; Pawelek, K.A.; Harrington, K.; Cangelosi, R.; Madrid, S. Immune control of equine infectious anemia virus infection by CTLs and antibodies. Appl. Math. 2013, 4, 171-177.
18. Ciupe, S.; Schwartz, E.J. Understanding virus-host dynamics following EIAV infection in SCID horses. J. Theor. Biol. 2014, 343, 1-8.
19. Smith, R.J.; Schwartz, E.J. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: How often should you vaccinate and how strong should the vaccine be? Math. Biosci. 2008, 212, 180-187.
20. Konrad, B.P.; Vaidya, N.K.; Smith, R.J. Modelling mutation to a cytotoxic T-lymphocyte HIV vaccine. Math. Pop. Stud. 2011, 18, 122-149.
21. Bainov, D.D.; Simeonov, P.S. Systems with Impulsive Effect; Ellis Horwood Ltd.: Chichester, UK, 1989.
22. Bainov, D.D.; Simeonov, P.S. Impulsive differential equations: Periodic solutions and applications; Longman Scientific and Technical; Burnt Mill: Essex, UK, 1993.
23. Bainov, D.D.; Simeonov, P.S. Impulsive Differential Equations: Asymptotic Properties of the Solutions; World Scientific: Singapore City, Singapore, 1995.
24. Lakshmikantham, V.; Bainov, D.D.; Simeonov, P.S. Theory of Impulsive Differential Equations; World Scientific: Singapore City, Singapore, 1989.
25. Agur Z.; Cojocaru, L.; Mazor, G.; Anderson, R.; Danon, Y. Pulse mass measles vaccination across age cohorts. Proc. Natl. Acad. Sci. USA 1993, 90, 11698-11702.
26. Stone L.; Olinky, R.; Huppert, A. Seasonal dynamics of recurrent epidemics. Nature 2007, 446, 533-536.
27. Miron, R.E.; Smith, R.J. Modelling imperfect adherence to HIV induction therapy. BMC Infect. Dis. 2010, 10, doi:10.1186/1471-2334-10-6.
28. Roberts, M.G.; Kao, R.R. The dynamics of an infectious disease in a population with birth pulses. Math. Biosci. 1998, 149, 23-36.
29. Al-arydah, M.; Smith, R.J.; Lutscher, F. Modelling gender-structured wildlife diseases with harvesting: Chronic Wasting Disease as an example. ISRN Biomath. 2012, 2012, doi:10.5402/2012/802450.
30. Kot, M. Elements of Mathematical Ecology; Cambridge University Press: Cambridge, UK, 2001.
31. Schwartz, E.J.; Neumann, A.U.; Teixeira, A.V.; Bruggeman, L.A.; Rappaport, J.; Perelson, A.S.; Klotman, P.E. Effect of target cell availability on HIV-1 production in vitro. AIDS 2002, 16, 341-345.
32. Waldmann, T.A.; Strober, W. Metabolism of immunoglobulins. Prog. Allergy 1969, 13, 1-110.
33. +T cell depletion on virus replication in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J. Exp. Med. 2000, 191, 1921-1931.
34. Nowak, M.A.; Lloyd, A.L.; Vasquez, G.M.; Wiltrout, T.A.; Wahl, L.M.; Bischofberger, N.; Williams, J.; Kinter, A.; Fauci, A.S.; Hirsch, V.M.; et al. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J. Virol. 1997, 71, 7518-7525.
35. +-cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J. Virol. 2004, 78, 5324-5337.
36. Mansky, L.M.; Temin, H.M. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 1995, 69, 5087-5094.
37. Bryan, W.R. Interpretation of host response in quantitative studies on animal viruses. Ann. NY Acad. Sci. 1957, 69, 698-728.
38. Ramratnam, B.; Bonhoeffer, S.; Binley, J.; Hurley, A.; Zhang, L.; Mittler, J.E.; Markowitz, M.; Moore, J.P.; Perelson, A.S.; Ho, D.D. Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet 1999, 354, 1782-1785.
39. Heffernan, J.M.; Smith, R.J.; Wahl, L.M. Perspectives on the basic reproductive ratio. J. R. Soc. Interface 2005, 2, 281-293.
40. Schwartz, E.J.; Vaidya, N.K.; Dorman, K.; Carpenter, S.; Mealey, R.H. Dynamics of lentiviral infection in vivo in the absence of adaptive host immune responses. J. Virol., submitted for publication, 2014.
41. Blower, S.M.; Dowlatabadi, H. Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example. Int. Stat. Rev. 1994, 2, 229-243.
42. Schwartz, E.J.; Blower, S. Predicting the potential individual-and population-level effects of imperfect herpes simplex virus type 2 vaccines. J. Infect. Dis. 2005, 191, 1734-1746.
43. Schwartz, E.J.; Bodine, E.N.; Blower, S. Effectiveness and efficiency of imperfect therapeutic HSV-2 vaccines. Hum. Vaccines 2007, 3, 231-238.
44. Smith, R.J.; Cloutier, P.; Harrison, J.; Desforges, A. A mathematical model for the eradication of Guinea Worm Disease. In Understanding the Dynamics of Emerging and Re-Emerging Infectious Diseases Using Mathematical Models; Mushayabasa, S., Bhunu, C.P. Eds.; Transworld Research Network: Kerala, India, 2012; pp. 133-156.
45. Schwartz, E.J.; Nanda, S. Antibody Escape Kinetics of EIAV Infection of Horses. J. Virol., submitted for publication, 2014.
46. Tschetter, J.R.; Byrne, K.M.; Perryman, L.E.; McGuire, T.C. Control of equine infectious anemia virus is not dependent on ADCC mediating antibodies. Virology 1997, 230, 275-280.
47. 0. Comp. Math. Methods Med. 2011, 2011, doi:10.1155/2011/527610.